BEDFORD, Mass.--(BUSINESS WIRE)--NinePoint Medical, Inc., a transformative medical device company pioneering the use of advanced Optical Coherence Tomography (OCT) for gastrointestinal applications, will be featuring the NvisionVLE® Imaging System with Real-time Targeting™ at Digestive Disease Week® (DDW) 2017, which will be held May 6-9 in Chicago. In addition, results from various studies utilizing this technology in gastroenterology will be presented in 24 scientific abstracts throughout the conference.
Random biopsy is the current standard of care for diagnosing esophageal diseases such as Barrett’s esophagus, squamous cell carcinoma, and adenocarcinoma. However, random biopsies assess less than 3% of the esophageal surface1, leaving more than 97% of the tissue un-sampled. The NvisionVLE Imaging System rapidly evaluates 100% of the esophageal tissue at a depth of 3mm and may identify disease that is not visible with conventional medical imaging technologies such as endoscopy or ultrasound. Now, with the addition of the Real-time Targeting feature, physicians can not only locate, but also mark areas of interest for targeted biopsy or treatment.
“Real-time Targeting has increased my confidence in detecting and targeting potential disease that may exist below the surface of the esophagus,” stated Dr. Kenneth Chang, MD, University of California Irvine Medical Center, Professor and Chief, Division of Gastroenterology. “Finding dysplastic or cancerous cells in patients with Barrett’s Esophagus can be like looking for a needle in a haystack. This technology may help us not only in finding the needle, but also in determining the most effective therapy. It has become an integral part of my practice.”
Ad Statistics
Times Displayed: 113476
Times Visited: 6766 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
“We are very appreciative of the many clinicians who have contributed to the rapidly growing body of scientific evidence supporting the use of Optical Coherence Tomography (OCT) in gastroenterology, through their many abstract submissions for DDW 2017,” stated Christopher von Jako, PhD., President and CEO of NinePoint Medical. “We are excited to showcase our new Real-time Targeting feature, which has transformed the clinical use of OCT and is helping physicians find disease earlier, so it can be treated effectively.”
NinePoint Medical will be exhibiting at booth # 4028 during DDW 2017.
About Esophageal Disease
Esophageal adenocarcinoma (EAC) is the fastest growing cancer in the western world, increasing in incidence more than 7-fold over the past several decades.2 Barrett’s esophagus, a complication of gastroesophageal reflux disease (GERD), affects more than 12 million American adults,3 and is associated with a 30-fold increased risk of developing EAC.4
